my request was to give some contour to my jawline, believing that filler in that area would help Mandie explained that I actually needed to work on the cheeks/chin instead & she was absolutely right.I am over the moon with my results & Mandie is so gentle that it didnt hurt one bit.She is the best in the industry & I wouldnt use anyone else

Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome

doi:10.1371/journal.pone.0033944 Lederman RJ, Mendelsohn FO, Anderson RD, Saucedo JF, Tenaglia AN, Hermiller JB, Hillegass WB, Rocha-Singh K, Moon TE, Whitehouse MJ et al (2002) Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial
So, we have 5,000mcg of BPC-157 in 200 units of solution
The THRIVE difference Boutique, provider-directed care from Kristine Kjolhede, FNP-C with physician supervision proper sourcing, individualized dosing, honest evidence, and real follow-up, for patients across Lakeway, Bee Cave, Lake Travis, and greater Austin